Company / Accounts Receivable
Valion Bio, Inc. Accounts Receivable History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$69.0K
FY2024
5-year range
$69.0K / $174.0K
FY2022-FY2024
Trend
-60.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $88,000 to $69,000 over the past 2 years.
Based on SEC 10-K filings.
$69,000 in FY2024.
Declined from $88,000 to $69,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, accounts receivable decreased 60.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $69.0K | -60.3% |
| FY2023 | $174.0K | +97.7% |
| FY2022 | $88.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026